NCT06567704 Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
| NCT ID | NCT06567704 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-03-26 |
| Primary Completion | 2026-08-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years of age at the time of consent. * Must be able to speak, read, and understand English. * Participants diagnosed with NSCLC, and: * have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or * have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or * who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment * Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments) * Have completed at least two cycles of immunotherapy. * Self-reported cancer-related fatigued that impacts daily function. Exclusion Criteria: * Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months * Participants who have received radiation the
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.